Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
New Managers September 2012

Perspectives - Recent views and findings of interest to new hedge fund managers

PerTrac: most of H1 gains came from small or start-up funds, but most inflows went to billion-dollar club

The total, reported amount invested within the hedge fund industry, including funds of hedge funds and CTAs, climbed to $2.317 trillion in the first six months of 2012, according to PerTrac, the database provider. The total number of all funds reporting to databases also jumped by 4.61% to 14,013, led by single-manager hedge funds, whose ranks swelled 7.46% to 10,754 funds.

Most of the gains in the number of single-manager hedge funds (75%) came from small and start-up funds with less than $25 million in AuM.

Even if the gains came from small funds and start-ups, investors who allocated to alternatives in 2012 favored the largest funds, PerTrac notes. The "billion dollar club" of single-manager hedge funds, those that oversee more than $1 billion, saw AuM increase to $1.146 trillion from $1.08 trillion at the end of 2011. The billion-dollar-plus funds represented 60% of all assets invested with single-manager hedge funds at the end of H1-2012.

FRM: strategies are important criteria for seeders

During the recent Opalesque Roundtable in London, participant Blaine Tomlinson, founder of fund of funds group Financial Risk Management (FRM) commented on the firm's recent acquisition by Man Group, the future for funds of funds and the development of FRM's seeding business, which has been running since 2007.

It is important to be very selective in terms of the strategies, he commented. "Do we think a part......................

To view our full article please login

This article was published in Opalesque's New Managers a top-down monthly analysis, news and research publication on the global emerging manager space.
New Managers
New Managers
New Managers

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for